XML 15 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash flows from operating activities:    
Net income (loss) $ (2,392,189) $ (1,293,569)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization expense 692,991 661,485
Deferred tax expense 0 758,112
Share-based compensation 339,209 254,585
Excess tax (benefit) expense derived from exercise of stock options   (92,741)
Noncash interest expense 18,303 26,778
Noncash investment gains 43,338 4,807
Net changes in assets and liabilities affecting operating activities:    
Accounts receivable (2,093,950) (2,395,348)
Inventories (76,323) 275,175
Other current assets and other assets (600,884) (132,819)
Accounts payable and other current liabilities (1,254,535) (1,216,345)
Other long-term liabilities 103,991 92,881
Net cash provided by operating activities 235,589 1,439,371
Cash flows from investing activities:    
Additions to property and equipment (94,881) (123,945)
Purchases of marketable securities (15,151,948) (792,716)
Proceeds from sale of marketable securities 4,257,657 941,087
Additions to intangible assets (532,954) (453,961)
Net cash used in investing activities (11,522,126) (429,535)
Cash flows from financing activities:    
Borrowings on line of credit 12,000,000 0
Repayments on line of credit (9,800,000) 0
Sales of shares of common stock, net of offering costs 200,909 0
Payments of deferred offering costs (248,108) 0
Repurchase of common shares (1,016,156) (545,924)
Net cash provided by (used in) financing activities 1,136,645 (545,924)
Net increase (decrease) in cash and cash equivalents (10,149,892) 463,912
Cash and cash equivalents at beginning of period 45,412,868 34,510,330
Cash and cash equivalents at end of period $ 35,262,976 $ 34,974,242